Albert Einstein College of Medicine researchers receive $5 million NIH grant to study HIV and HPV cancers in Africa

Rose Blan

IMAGE: Kathryn Anastos, M.D. view more  Credit: Albert Einstein College of Medicine November 13, 2020–(BRONX, NY)–A team of scientists from Albert Einstein College of Medicine has received a five-year, $4.9 million grant from the National Institutes of Health (NIH) to establish a research center to investigate HIV- and human papillomavirus (HPV)-related […]

IMAGE

IMAGE: Kathryn Anastos, M.D.
view more 

Credit: Albert Einstein College of Medicine

November 13, 2020–(BRONX, NY)–A team of scientists from Albert Einstein College of Medicine has received a five-year, $4.9 million grant from the National Institutes of Health (NIH) to establish a research center to investigate HIV- and human papillomavirus (HPV)-related cancers in Africa.

The HIV-Associated HPV-related Malignancies Research Center will build on Einstein-led efforts that have already improved research, clinical, and laboratory capacity in Rwanda. More than 200,000 people in Rwanda have HIV, and women have a higher burden of the disease, according to the Centers for Disease Control and Prevention. Additionally, cervical cancer, which is caused by HPV and which women with HIV are at greater risk of developing, is one of the two most common malignancies among Rwandan women. HPV is also linked to the development of anal, penile, and head and neck cancers.

The grant will enable Einstein researchers and their partners to expand the Rwandan programs and launch similar initiatives in the Democratic Republic of the Congo (DRC). These efforts will help improve health outcomes for millions of Africans living with HIV whose incidence of diseases, including cancer, is increasing as they live longer due to effective HIV therapies.

“We aim to develop a cadre of Rwandan and DRC scientific leaders and build the necessary physical and administrative infrastructure to launch and sustain this project,” said Kathryn Anastos, M.D., lead investigator on the grant and a member of the Albert Einstein Cancer Center, which has supported previous work in Rwanda, including efforts to bring Rwandans to the United States to train.

“Our new NIH-funded center in Africa will serve as a national and regional resource hub for research, training, and career development for those studying the epidemiology, pathogenesis, prevention, and treatment of HPV-associated malignancies in people living with HIV,” added Dr. Anastos, who is professor of medicine, of epidemiology & population health, and of obstetrics & gynecology and women’s health at Einstein and an internist at Montefiore Health System.

Dr. Anastos is recognized internationally for her clinical and investigative work in HIV-infected women, and she has long been involved in leading complex multi-faceted research projects in the United States and Rwanda. Other principal investigators on the grant are Adebola Adedimeji, Ph.D., M.B.A., research associate professor of epidemiology & population heath, and Marcel Yotebieng, M.D., Ph.D., M.P.H., associate professor of medicine, both from Einstein, and Leon Mutesa, M.D., Ph.D., professor of human genetics and director of the Center for Human Genetics at the College of Medicine and Health Sciences-University of Rwanda. The Einstein team includes more than a dozen other faculty members from a range of departments and specialties, including several from the Albert Einstein Cancer Center. They will partner with three African institutions: University of Rwanda, Rwanda Military Hospital, and Université Protestante au Congo.

The grant will support two research projects. One is the first population-based assessment of the effectiveness of HPV vaccination in women living with HIV. The study also will compare the HPV antibody response of those who received a three-dose vaccination, implemented in 2011, to women who received a two-dose vaccination schedule, starting in 2015. The second project, in its fourth year in Rwanda and new to DRC, will focus on HPV prevalence and disease burden in men who have sex with men (MSM).

“Our studies can help inform national policies on HPV vaccinations for MSM and the development of targeted screening in men who are too old to benefit from vaccination,” said Dr. Yotebieng. “New policies can directly impact the susceptibility of people living with HIV to develop HPV-related malignancies.”

Both projects will include additional studies on the interaction of the gut microbiome with cervical, anal, and penile HPV infections. Central to those studies and the growth of the research center will be the development of laboratory capacity in molecular diagnostics in DRC, and in next generation DNA and RNA sequencing (which is faster and less expensive than older technologies) in Rwanda. In addition, the grant enables scientific leaders to continue their support of master’s and doctorate level education for team members in Africa.

“We are looking forward to training twenty people with our grant, including clinicians and others who will learn research techniques, lab methods, clinical skills, and manuscript writing so they can publish their findings,” said Dr. Adedimeji. “The one-on-one mentoring and development of skills will ensure that the research can be disseminated and expanded over time and that we can reach more people in Rwanda and DRC to help improve their health outcomes.”

The grant, titled “Einstein/Rwanda/DRC Consortium for Research in HIV/HPV/Malignancies,” was funded by the National Cancer Institute, part of the NIH (1U54CA254568-01).

###

About Albert Einstein College of Medicine

Albert Einstein College of Medicine is one of the nation’s premier centers for research, medical education and clinical investigation. During the 2019-20 academic year, Einstein is home to 724 M.D. students, 158 Ph.D. students, 106 students in the combined M.D./Ph.D. program, and 265 postdoctoral research fellows. The College of Medicine has more than 1,800 full-time faculty members located on the main campus and at its clinical affiliates. In 2019, Einstein received more than $178 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States through Montefiore and an affiliation network involving hospitals and medical centers in the Bronx, Brooklyn and on Long Island. For more information, please visit http://www.einstein.yu.edu, read our blog, follow us on Twitter, like us on Facebook, and view us on YouTube.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Source Article

Next Post

Fitness & Organics Announces an Attractive Discount on All Orders over $100

Fitness and Organics announces a 25 percent discount on all orders above $100for a limited period. Fitness and Organics, the leading fitness hub for finding information about innovative fitness, health, and wellness products, has announced a discount of 25 percent on all orders above $100. Fitness enthusiasts can buy workout […]